DA-8010 2.5mg

DRUG2 trials

Sponsors

Dong-A ST Co., Ltd.

Conditions

Overactive Bladder

Phase 2

A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

CompletedNCT03566134

Dong-A ST Co., Ltd.Overactive Bladder

Start: 2018-07-10End: 2019-12-27Updated: 2020-02-07

Phase 3

A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

CompletedNCT05282069

Dong-A ST Co., Ltd.Overactive Bladder

Start: 2022-05-12End: 2024-05-29Updated: 2024-06-26

Related Papers

Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study

International Neurourology Journal2022-06-299 citations